XBIO - ゼネティック・バイオサイエンシズ (Xenetic Biosciences Inc.) ゼネティック・バイオサイエンシズ

 XBIOのチャート


 XBIOの企業情報

symbol XBIO
会社名 Xenetic Biosciences Inc (ゼネティック・バイオサイエンシズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Xenetic Biosciences Inc. is a clinical-stage biopharmaceutical company. The Company focuses on discovery research and development of biologic drugs and novel oncology therapeutics. The Company’s lead investigational product candidate is oncology therapeutic XBIO-101 which is used for the treatment of progestin - resistant endometrial cancer. The Company is currently conducting a Phase 2 trial for XBIO-101. The Company’s lead proprietary technology is PolyXen which enables platform technology that can be applied to protein or peptide therapeutics using the natural polymer polysialic acid. The Company’s technology includes XBIO-101 PolyXen OncoHist ErepoXen and ImuXen. ErepoXen or polysialylated erythropoietin is an internal drug candidate which uses the company’s PolyXen platform technology for the treatment of anemia in chronic kidney disease (CKD) patients.   ゼネティック・バイオサイエンシズは米国のバイオ医薬品企業。同社パイプラインには、がんの兆候を治療する「OncoHist」、シアル酸の連鎖を利用するテクノロジ―「PolyXen」、ワクチンを作成するリボソ―ム型封入技術「ImuXen」などがある。英国のゼネティック・バイオサイエンシズを通し臨床段階での開発に従事する。本社はマサチュ―セッツ州レキシントン。   Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART™ has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.
本社所在地 99 Hayden Ave. Suite 230 Lexington MA 02421 USA
代表者氏名 Jeffrey F. Eisenberg ジェフリーF.アイゼンバーグ
代表者役職名 Chief Executive Officer Chief Operating Officer Director
電話番号 +1 781-778-7720
設立年月日 40756
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 5人
url www.xeneticbio.com
nasdaq_url https://www.nasdaq.com/symbol/xbio
adr_tso
EBITDA EBITDA(百万ドル) -1.60962
終値(lastsale) 2.4287
時価総額(marketcap) 22839225.2143
時価総額 時価総額(百万ドル) 22.38126
売上高 売上高(百万ドル) 7.58500
企業価値(EV) 企業価値(EV)(百万ドル) 19.12591
当期純利益 当期純利益(百万ドル) -1.65928
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Xenetic Biosciences Inc revenues was not reported. Net loss decreased 33% to $3.8M. Lower net loss reflects General and administrative decrease of 39% to $2.2M (expense) Research and development decrease of 22% to $1.6M (expense) Other income (expense) decrease of 22% to $27K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.67 to -$0.44.

 XBIOのテクニカル分析


 XBIOのニュース

   Stock Mover: Xenetic Biosciences, Inc. (NASDAQ:XBIO), Great Panther Mining Limited (AMEX:GPL)  2021/06/14 22:55:36 Stock Equity
Xenetic Biosciences, Inc. (NASDAQ:XBIO) with the stream of 14.55% also noticed, India Great Panther Mining Limited (AMEX:GPL) encountered a rapid change of -1.66% in the last hour of Mondays trading The post Stock Mover: Xenetic Biosciences, Inc. (NASDAQ:XBIO), Great Panther Mining Limited (AMEX:GPL) appeared first on Stocks Equity .
   Xenetic Biosciences (XBIO) Investor Presentation - Slideshow  2021/05/21 19:41:27 Seeking Alpha
   Xenetic Biosciences Inc (XBIO) falls 2.2% for May 19  2021/05/19 22:00:22 Equities
Xenetic Biosciences Inc (NASDAQ: XBIO) shares fell -2.20% to end trading Wednesday at $1.84 per share - a net change of $-0.04. Shares traded between $1.86 and $1.77 throughout the day. 33848 shares of Xenetic Biosciences Inc exchanged hands. Visit Xenetic Biosciences Incs profile for more information. About The Nasdaq Stock Market The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world\''s leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook. To get more information on Xenetic Biosciences Inc and to follow the companys latest updates, you can visit the companys profile page here: Xenetic Biosciences Incs Profile . For more news on the financial markets be sure to visit Equities News . Also, dont forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week. Sources: Chart is provided by TradingView based on 15-minute-delayed prices.
   Xenetic Biosciences: Q1 Earnings Snapshot  2021/05/12 12:09:07 CityNews Vancouver
FRAMINGHAM, Mass. (AP) _ Xenetic Biosciences, Inc. (XBIO) on Wednesday reported a loss of $1.3 million in its first quarter. The Framingham, Massachusetts-based company said it had a loss of 15 cents per share. The company posted revenue of $191,200 in the period. Its adjusted revenue was $191,000. The companys shares closed at $1.79. A []
   Xenetic Biosciences Inc. Shares Close the Week 24.1% Lower - Weekly Wrap  2021/02/26 22:30:00 Kwhen Finance
Xenetic Biosciences Inc. shares closed this week 24.1% lower than it did at the end of last week. The stock is currently up 17.2% year-to-date, up 141.9% over the past 12 months, and down 98.3% over the past five years. This week, the Dow Jones Industrial Average fell 1.7%, and the S&P 500 fell 2.5%. Trading Activity Shares traded as high as $3.08 and as low as $2.33 this week.Shares closed 6e+1% below its 52-week high and 5e+2% above its 52-week low.Trading volume this week was 20.5% higher than the 10-day average and 10.0% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.7. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price lags the S&P 500 Index this week, beats it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, beats it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector this week, beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -370.1% The company's stock price performance over the past 12 months beats the peer average by 370.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Xenetic Biosciences (XBIO) Investor Presentation - Slideshow  2021/05/21 19:41:27 Seeking Alpha
   Xenetic Biosciences Inc (XBIO) falls 2.2% for May 19  2021/05/19 22:00:22 Equities
Xenetic Biosciences Inc (NASDAQ: XBIO) shares fell -2.20% to end trading Wednesday at $1.84 per share - a net change of $-0.04. Shares traded between $1.86 and $1.77 throughout the day. 33848 shares of Xenetic Biosciences Inc exchanged hands. Visit Xenetic Biosciences Incs profile for more information. About The Nasdaq Stock Market The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world\''s leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook. To get more information on Xenetic Biosciences Inc and to follow the companys latest updates, you can visit the companys profile page here: Xenetic Biosciences Incs Profile . For more news on the financial markets be sure to visit Equities News . Also, dont forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week. Sources: Chart is provided by TradingView based on 15-minute-delayed prices.
   Xenetic Biosciences: Q1 Earnings Snapshot  2021/05/12 12:09:07 CityNews Vancouver
FRAMINGHAM, Mass. (AP) _ Xenetic Biosciences, Inc. (XBIO) on Wednesday reported a loss of $1.3 million in its first quarter. The Framingham, Massachusetts-based company said it had a loss of 15 cents per share. The company posted revenue of $191,200 in the period. Its adjusted revenue was $191,000. The companys shares closed at $1.79. A []
   Xenetic Biosciences Inc. Shares Close the Week 24.1% Lower - Weekly Wrap  2021/02/26 22:30:00 Kwhen Finance
Xenetic Biosciences Inc. shares closed this week 24.1% lower than it did at the end of last week. The stock is currently up 17.2% year-to-date, up 141.9% over the past 12 months, and down 98.3% over the past five years. This week, the Dow Jones Industrial Average fell 1.7%, and the S&P 500 fell 2.5%. Trading Activity Shares traded as high as $3.08 and as low as $2.33 this week.Shares closed 6e+1% below its 52-week high and 5e+2% above its 52-week low.Trading volume this week was 20.5% higher than the 10-day average and 10.0% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.7. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price lags the S&P 500 Index this week, beats it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, beats it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector this week, beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -370.1% The company's stock price performance over the past 12 months beats the peer average by 370.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Xenetic Biosciences Inc. Shares Close the Day 11.8% Lower - Daily Wrap  2021/02/25 22:30:00 Kwhen Finance
Xenetic Biosciences Inc. shares closed today 11.8% lower than it did at the end of yesterday. The stock is currently up 32.8% year-to-date, up 150.9% over the past 12 months, and down 98.1% over the past five years. Today, the Dow Jones Industrial Average fell 1.4%, and the S&P 500 fell 0.5%. Trading Activity Shares traded as high as $3.35 and as low as $2.49 this week.Shares closed 6e+1% below its 52-week high and 4e+2% above its 52-week low.Trading volume this week was 46.1% lower than the 10-day average and 56.7% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price lags the S&P 500 Index today, beats it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, beats it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector today, beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -802.5% The company's stock price performance over the past 12 months beats the peer average by 439.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Life Sciences Conference  2021/03/03 13:05:00 Yahoo Finance
FRAMINGHAM, MA / ACCESSWIRE / March 3, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, announced today that Jeffrey Eisenberg, Chief Executive Officer of Xenetic will present at the virtual H.
   Why Nano-Cap Xenetic Biosciences Is Skyrocketing  2020/12/09 20:41:24 Benzinga
Shares of Xenetic Biosciences Inc (NASDAQ: XBIO ), a drug delivery platform company, were ripping higher Wednesday on markedly above-average volume. What Happened: The Framingham, Massachusetts-based company said its partner and Russian biopharma PJSC Pharmsynthez reported positive data from a pivotal Phase 3 study of Epolong that used Xenetic's PolyXen to develop a treatment for anemia in patients with chronic kidney disease. PolyXen is Xenetic's patent-protected platform technology designed for prolonging a biologic drug's circulating half-life and potentially improving other pharmacological properties. Pharmsynthez's late-stage study being conducted in Russia is evaluating the safety … Full story available on Benzinga.com
   Thinking about buying stock in Xenetic Biosciences, Sundial Growers, Norwegian Cruise Line, Delta Air Lines, or Callon Petroleum? - Stocks News Feed  2020/12/09 16:21:00 Stocks News Feed
NEW YORK, Dec. 9, 2020 /PRNewswire/ — InvestorsObserver issues critical PriceWatch Alerts for XBIO, SNDL, NCLH, DAL, and CPE. To see how InvestorsObserver’s proprietary scoring system rates these stocks, view the InvestorsObserver’s PriceWatch Alert by selecting the corresponding link. (Note: You may have to copy this link into your browser then press the [ENTER] key.) InvestorsObserver’s… Read More »Thinking about buying stock in Xenetic Biosciences, Sundial Growers, Norwegian Cruise Line, Delta Air Lines, or Callon Petroleum?
   Xenetic Biosciences News: Why XBIO Stock Is Going Ballistic Today  2020/12/09 15:51:50 InvestorPlace
Xenetic Biosciences (XBIO) news for Wednesday includes positive news from a Phase 3 clinical trial boosting XBIO stock higher.
   Xenetic Biosciences Inc Analysts Estimate Report : What to Look Out for Stock market Insights & financial analysis  2020/11/27 18:00:00 Stock Market Daily
Xenetic Biosciences Inc announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ゼネティック・バイオサイエンシズ XBIO Xenetic Biosciences Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)